Что нового? Обзор международных публикаций за 2016г., посвященных проблемам эффективности и безопасности нестероидных противовоспалительных препаратов

Нестероидные противовоспалительные препараты (НПВП) – основное средство патогенетической терапии острой и хронической боли, связанной с ревматическими заболеваниями. Казалось бы, НПВП прекрасно изучены: известны их фармакологические свойства, определены области применения, эффективность при различных заболеваниях и патологических состояниях, возможные нежелательные реакции и методы их профилактики. И тем не менее эта лекарственная группа до настоящего времени остается одной из наиболее обсуждаемых в мировой медицинской литературе. Не утихают споры о терапевтической ценности НПВП, соотношении их лечебного потенциала и риска осложнений, целесообразности длительного применения при ряде нозологических форм. Постоянно появляются сообщения о новых исследованиях, результаты которых изменяют сложившееся мнение о многих аспектах использования НПВП в реальной клинической практике. Представлен краткий обзор некоторых наиболее интересных и значимых работ, посвященных НПВП, появившихся в мировой медицинский печати за минувший 2016 г.

1. Danelich IM, Wright SS, Lose JM, et al. Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Pharmacotherapy. 2015 May;35(5):520-35. doi: 10.1002/phar.1584. Epub 2015 May 4.

2. Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti- inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.

3. Nelson AE, Allen KD, Golightly YM, et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014 Jun;43(6):701-12. doi: 10.1016/j.semarthrit.2013.11.012. Epub 2013 Dec 4.

4. McCarberg BH. NSAIDs in the older patient: balancing benefits and harms. Pain Med. 2013 Dec;14 Suppl 1:S43-4. doi: 10.1111/pme.12253.

5. Richette P, Latourte A, Frazier A. Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? Expert Opin Drug Saf. 2015 Aug;14(8):1259-68. doi: 10.1517/14740338.2015.1056776. Epub 2015 Jul 1.

6. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

7. Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. doi: 10.1016/j.semarthrit.2015.11.009. Epub 2015 Dec 2.

8. Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti- inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet. 2016 May 21;387(10033):2093-105. doi: 10.1016/S0140-6736(16)30002-2. Epub 2016 Mar 18.

9. Mayor S. Paracetamol does not reduce pain or improve function in osteoarthritis, study shows. BMJ. 2016 Mar 17;352:i1609. doi: 10.1136/bmj.i1609.

10. Moore N , Salvo F, Duong M, Gulmez SE. Does paracetamol still have a future in osteoarthritis? Lancet. 2016 May 21;387 (10033):2065-6. doi: 10.1016/S0140-6736(15)01170-8. Epub 2016 Mar 18.

11. Mut. Paracetamol in knee and hip arthrosis is dispensable. MMW Fortschr Med. 2016 Apr 14;158(7):9. doi: 10.1007/s15006-016-8031-5.

12. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non- inferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14.

13. Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non- steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016 Jun;24(6):962-72. doi: 10.1016/j.joca.2016.01.135. Epub 2016 Feb 1.

14. Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S18-21. doi: 10.1016/j.semarthrit.2015.11.007. Epub 2015 Dec 2.

15. Derry S, Conaghan P, da Silva JA, et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016 Apr 22;4:CD007400. doi: 10.1002/14651858.CD007400.pub3.

16. Goodson N, Brookhart A, Symmons D, et al. Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis. 2009 Mar;68(3): 367-72. doi: 10.1136/ard.2007.076760. Epub 2008 Apr 13.

17. Lee T, Bartle B, Weiss K. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. Am J Med. 2007 Jan;120(1):98.e9-16.

18. Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti- inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016 Sep 8:1-14. [Epub ahead of print].

19. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Nov 13. [Epub ahead of print].

20. Arfе A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.

21. Sondergaard KB, Weeke P, Wissenberg M, et al. Non-steroidal anti-inflammatory drug use is associated with increased risk of outof- hospital cardiac arrest: a nationwide casetime-control study. Eur Heart J Cardiovasc Pharmacother. 2016 Dec 26. pii: pvw041. doi: 10.1093/ehjcvp/pvw041. [Epub ahead of print].

22. De Souza Brito F, Mehta RH, Lopes RD, et al. Non-Steroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. Am J Med. 2016 Nov 22. pii: S0002-9343(16) 31197-4. doi: 10.1016/j.amjmed.2016.10.023. [Epub ahead of print].

23. Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin Nonsteroidal Anti- Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta- Analysis of Observational Studies. Stroke. 2016 Feb;47(2):356-64. doi: 10.1161/STROKEAHA.115.011678. Epub 2015 Dec 15.

24. Lee T, Lu N, Felson DT, et al. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population- based case-control study. Rheumatology (Oxford). 2016 Jun;55(6): 1099-105. doi: 10.1093/rheumatology/kew036. Epub 2016 Mar 15.

25. Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016 Mar;43(3):607-17. doi: 10.3899/jrheum.150721. Epub 2016 Feb 1.

26. Rasmussen-Barr E, Held U, Grooten WJ, et al. Non-steroidal anti-inflammatory drugs for sciatica. Cochrane Database Syst Rev. 2016 Oct 15;10:CD012382.

27. Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi: 10.1002/14651858.CD012087.

28. Kress HG, Baltov A, Basinski A, et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin. 2016;32(1):23-36. doi: 10.1185/03007995.2015.1100986. Epub 2015 Oct 15.

29. Кресс Х, Каратеев АЕ, Кукушкин МЛ. Эффективный контроль боли: научно обоснованные терапевтические подходы. Русский медицинский журнал. 2016;(12):757- 64. [Kress Kh, Karateev AE, Kukushkin ML. Effective pain control: evidence-based therapeutic approaches. Russkii meditsinskii zhurnal. 2016;(12): 757-64. (In Russ.)].

30. Donati M, Conforti A, Lenti MC, et al. Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy. Br J Clin Pharmacol. 2016 Jul;82(1):238-48. doi: 10.1111/bcp.12938. Epub 2016 Apr 27.

31. Traversa G, Bianchi C, da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other nonsteroidal antiinflammatory drugs. BMJ. 2003 Jul 5; 327(7405):18-22.

32. Takeuchi K, Satoh H. NSAID-induced small intestinal damage – roles of various pathogenic factors. Digestion. 2015;91(3):218-32. doi: 10.1159/000374106. Epub 2015 Mar 18.

33. Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal antiinflammatory drug-enteropathy. World J Gastroenterol. 2013 Mar 28;19(12):1861-76. doi: 10.3748/wjg.v19.i12.1861.

34. Tacheci I, Bradna P, Douda T, et al. Small intestinal injury in NSAID users suffering from rheumatoid arthritis or osteoarthritis. Rheumatol Int. 2016 Nov;36(11):1557-61. Epub 2016 Aug 22.

35. Gallo A, Passaro G, Gasbarrini A, et al. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol. 2016 Aug 28; 22(32):7186-202. doi: 10.3748/wjg.v22.i32.7186.

36. Rogers MA, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016 Feb;22(2):178.e1-9. doi: 10.1016/j.cmi.2015.10.003. Epub 2015 Oct 16.

37. Mayo SA, Song YK, Cruz MR, et al. Indomethacin injury to the rat small intestine is dependent upon biliary secretion and is associated with overgrowth of enterococci. Physiol Rep. 2016 Mar;4(6). pii: e12725. doi: 10.14814/phy2.12725. Epub 2016 Mar 31.

38. Lue A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. World J Gastroenterol. 2016 Dec 28;22(48):10477-81. doi: 10.3748/wjg.v22.i48.10477.

39. Singh DP, Borse SP, Nivsarkar M. Clinical importance of nonsteroidal antiinflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Transl Res. 2016 Sep;175:76-91. doi: 10.1016/j.trsl.2016.03.014. Epub 2016 Mar 29.

40. Scarpignato C, Dolak W, Lanas A, et al. Rifaximin Reduces Number and Severity of Intestinal Lesions Associated With use of Non-steroidal Anti-inflammatory Drugs in Humans. Gastroenterology. 2016 Dec 19. pii: S0016-5085(16)35504-4. doi: 10.1053/j.gastro.2016.12.007. [Epub ahead of print].

41. Long MD, Kappelman MD, Martin CF, et al. Role of Nonsteroidal Anti- Inflammatory Drugs in Exacerbations of Inflammatory Bowel Disease. J Clin Gastroenterol. 2016 Feb;50(2):152-6. doi: 10.1097/MCG.0000000000000421.